Relapsed refractory multiple myeloma with CNS involvement successfully treated with Elranatamab: first reported case
Yaşa Gül Mutlu, Süreyya Yiğit Kaya, Senem Maral, Elif Melek, Zafer Başlar, Leylagül Kaynar, Ömür Gökmen Sevindik
Abstract
Central nervous system (CNS) involvement in multiple myeloma (MM) is a rare and challenging complication associated with poor prognosis and limited treatment options. Emerging T-cell directing therapies, such as bispecific antibodies (bsAbs) and chimeric antigen receptor T cells (CAR-T), have shown remarkable success in treating MM, but their efficacy in CNS involvement remains unclear. Elranatamab, a humanized bispecific antibody targeting B-cell maturation antigen (BCMA) and CD3-expressing T cells, has demonstrated promising results in relapsed refractory MM. However, its efficacy in treating CNS-MM has not been reported. We present a case of a 37-year-old male MM patient with CNS involvement who has been successfully treated with Elranatamab.